Combined treatment strategies for microtubule stabilizing agent-resistant tumors

Journal of the National Cancer Institute

Volumn 107, Issue 4, 2015, Pages

  Broggini Tenzer, Angela ^a   Sharma, Ashish ^a   Nytko, Katarzyna J ^a   Bender, Sabine ^a   Vuong, Van ^a   Orlowski, Katrin ^a,c   Hug, Daniel ^a,b   O'Reilly, Terence ^a   Pruschy, Martin ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Novartis Pharma Switzerland   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BETA TUBULIN; BEVACIZUMAB; EPOTHILONE B; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; S6 KINASE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EPOTHILONE DERIVATIVE; MONOCLONAL ANTIBODY; RAPAMYCIN; RNA; TARGET OF RAPAMYCIN KINASE; TUBULIN MODULATOR; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CAPILLARY DENSITY; CONTROLLED STUDY; DRUG POTENCY; DRUG SENSITIZATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; LUNG NEOPLASMS; MICROTUBULE; NUDE MOUSE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; EVEROLIMUS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICE; MICE, NUDE; MICROTUBULES; PACLITAXEL; REAL-TIME POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUBULIN MODULATORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930729152     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju504     Document Type: Article

References (37)

1. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55(11):2325-2333.
2. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem. 1997;272(4):2534-2541.
3. Manfredi JJ, Parness J, Horwitz SB. Taxol binds to cellular microtubules. J Cell Biol. 1982;94(3):688-696.
4. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980;77(3):1561-1565.
5. Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer. 2000;1(1):32-40;discussion 41-42.
6. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18(3):623-631.
7. Altmann KH, Gertsch J. Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep. 2007;24(2):327-357.
8. He L, Yang CP, Horwitz SB. Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol Cancer Ther. 2001;1(1):3-10.
9. Nogales E. Structural insights into microtubule function. Annu Rev Biochem. 2000;69:277-302.
10. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta. 2000;1470(3):M79-M91.
11. Stein A. Ixabepilone. Clin J Oncol Nurs. 2010;14(1):65-71.
12. Raspaglio G, Filippetti F, Prislei S, et al. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene. 2008;409(1-2):100-108.
13. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10(3):194-204.
14. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997;100(5):1282-1293.
15. Bley CR, Jochum W, Orlowski K, et al. Role of the microenvironment for radiosensitization by patupilone. Clin Cancer Res. 2009;15(4):1335-1342.
16. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62(23):6938-6943.
17. Ferretti S, Allegrini PR, O'Reilly T, et al. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res. 2005;11(21):7773-7784.
18. Pasquier E, Carre M, Pourroy B, et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther. 2004;3(10):1301-1310.
19. Stalder MW, Anthony CT, Woltering EA. Metronomic dosing enhances the anti-angiogenic effect of epothilone B. J Surg Res. 2011;169(2):247-256.
20. Escuin D, Kline ER, Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res. 2005;65(19):9021-9028.
21. Furmanova-Hollenstein P, Broggini-Tenzer A, Eggel M, et al. The microtubule stabilizer patupilone counteracts ionizing radiation-induced matrix metalloproteinase activity and tumor cell invasion. Radiat Oncol. 2013;8:105.
22. Orlowski K, Rohrer Bley C, Zimmermann M, et al. Dynamics of tumor hypoxia in response to patupilone and ionizing radiation. PLoS One. 2012;7(12):e51476.
23. Rohrer Bley C, Orlowski K, Furmanova P, et al. Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells. Lung Cancer. 2011;73(3)294-301.
24. Faried LS, Faried A, Kanuma T, et al. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer. 2006;42(7):934-947.
25. Hurvitz SA, Dalenc F, Campone M, et al. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat. 2013;141(3):437-446.
26. Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004;10(20):7031-7042.
27. O'Reilly T, McSheehy PM, Wartmann M, et al. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs. 2011;22(1):58-78.
28. Sun JM, Kim JR, Do IG, et al. A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer. Br J Cancer. 2013;109(6):1482-1487.
29. Zhou Q, Wong CH, Lau CP, et al. Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. Int J Hepatol. 2013;2013:103830.
30. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676.
31. Hofstetter B, Vuong V, Broggini-Tenzer A, et al. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res. 2005;11(4):1588-1596.
32. Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009;15(5):1612-1622.
33. Jin K, Lan H, Cao F, et al. Differential response to EGFR-and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases. Int J Oncol. 2012;41(2):583-588.
34. Zhou F, Hu J, Shao JH, et al. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol. 2012;138(11):1879-1890.
35. Mickisch GH, Licht T, Merlino GT, et al. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res. 1991;51(19):5417-5424.
36. Laplante A, Demeule M, Murphy GF, et al. Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp. Transplant Proc. 2002;34(8):3393-3395.
37. Ishizuna K, Ninomiya J, Kojima M, et al. Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response because of addition of bevacizumab to paclitaxel therapy: a case report. BMC Res Notes. 2013;6(1):254.